Treatment: Radiation Therapy.

Radiation therapy (RT) is an integral part of treating all stages of lung cancer. Stereotactic ablative radiation therapy (SABR) has emerged as a standard treatment option for stage I-II patients with medically inoperable disease. Stage IIIA-IIIB disease is typically managed with definitive concurrent chemo-radiotherapy (CRT). Intensity modulated radiation therapy (IMRT) has enabled delivery of more potent RT dose while greatly limiting dose to surrounding normal organs, including lung, esophagus, and heart. SABR may have an expanding role in the treatment of stage IV patients, with new clinical trials exploring its combination with systemic immuotherapies.

[1]  E. Yorke,et al.  Local control and toxicity in a large cohort of central lung tumors treated with stereotactic body radiation therapy. , 2014, International journal of radiation oncology, biology, physics.

[2]  M. Anscher,et al.  Radiotherapy alone for medically inoperable stage I non-small-cell lung cancer: the Duke experience. , 1998, International journal of radiation oncology, biology, physics.

[3]  J. Herndon,et al.  Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. , 1996, Journal of the National Cancer Institute.

[4]  Lech Papiez,et al.  Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  S Kramer,et al.  A prospective randomized study of various irradiation doses and fractionation schedules in the treatment of inoperable non‐oat‐cell carcinoma of the lung. Preliminary report by the radiation therapy oncology group , 1980, Cancer.

[6]  Yoshihiro Ueda,et al.  Influence of rotational setup error on tumor shift in bony anatomy matching measured with pulmonary point registration in stereotactic body radiotherapy for early lung cancer. , 2012, Japanese journal of clinical oncology.

[7]  Jose Belderbos,et al.  Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Masahiro Hiraoka,et al.  Clinical outcomes of a phase I/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame. , 2005, International journal of radiation oncology, biology, physics.

[9]  Cynthia S. Johnson,et al.  Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  H. Groen,et al.  Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC): a meta-analysis of individual data from 1764 patients. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  A Harvey,et al.  Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomised multicentre trial. CHART Steering committee. , 1999, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[12]  Laura W. Christianson,et al.  Aggressive therapy for patients with non-small cell lung carcinoma and synchronous brain-only oligometastatic disease is associated with long-term survival. , 2014, Lung cancer.

[13]  D. Schrag,et al.  Comparative Effectiveness of Intensity-Modulated Versus 3D Conformal Radiation Therapy Among Medicare Patients with Stage III Lung Cancer , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[14]  Stephanie Frost,et al.  Extracranial stereotactic radioablation: results of a phase I study in medically inoperable stage I non-small cell lung cancer. , 2003, Chest.

[15]  J. Herndon,et al.  Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: Cancer and Leukemia Group B. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Walter J Curran,et al.  Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Lech Papiez,et al.  Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: four-year results of a prospective phase II study. , 2009, International journal of radiation oncology, biology, physics.

[18]  S. Hassenbusch,et al.  Nonsmall cell lung cancer presenting with synchronous solitary brain metastasis , 2006, Cancer.

[19]  Radhe Mohan,et al.  Initial evaluation of treatment-related pneumonitis in advanced-stage non-small-cell lung cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy. , 2007, International journal of radiation oncology, biology, physics.

[20]  L. Crinò,et al.  Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[21]  P. Iyengar,et al.  Phase II trial of stereotactic body radiation therapy combined with erlotinib for patients with limited but progressive metastatic non-small-cell lung cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  S. Kudoh,et al.  Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  C. Drake,et al.  Stereotactic radiation therapy combined with immunotherapy: augmenting the role of radiation in local and systemic treatment. , 2015, Oncology.

[24]  P. Blitzer,et al.  Radiation therapy in the management of medically inoperable carcinoma of the lung: results and implications for future treatment strategies. , 1992, International journal of radiation oncology, biology, physics.

[25]  W. Curran,et al.  Final Results of Phase III Trial in Regionally Advanced Unresectable Non-Small Cell Lung Cancer : Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group , 2000 .

[26]  Joe Y. Chang,et al.  Long-term outcomes after proton therapy, with concurrent chemotherapy, for stage II-III inoperable non-small cell lung cancer. , 2015, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[27]  M. Fotin‐Mleczek,et al.  mRNA-based vaccines synergize with radiation therapy to eradicate established tumors , 2014, Radiation oncology.

[28]  Yoshihiro Takai,et al.  A phase II study on stereotactic body radiotherapy for stage I non-small cell lung cancer. , 2007, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[29]  I. Lax,et al.  Long-term results of a prospective phase II trial of medically inoperable stage I NSCLC treated with SBRT – the Nordic experience , 2015, Acta oncologica.

[30]  S. Gettinger,et al.  Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small cell lung cancer (NSCLC). , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  N. O'Rourke,et al.  Concurrent chemoradiotherapy in non-small cell lung cancer. , 2010, The Cochrane database of systematic reviews.

[32]  Ian Poon,et al.  A comparison of two immobilization systems for stereotactic body radiation therapy of lung tumors. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[33]  W. Curran,et al.  Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. , 2015, The Lancet. Oncology.

[34]  C. Reddy,et al.  Prediction of chest wall toxicity from lung stereotactic body radiotherapy (SBRT). , 2009, International journal of radiation oncology, biology, physics.

[35]  R. Arriagada,et al.  Radiotherapy alone versus combined chemotherapy and radiotherapy in unresectable non-small cell lung carcinoma. , 1994, Lung cancer.

[36]  C. Onal,et al.  Definitive chemoradiation therapy following surgical resection or radiosurgery plus whole-brain radiation therapy in non-small cell lung cancer patients with synchronous solitary brain metastasis: a curative approach. , 2014, International journal of radiation oncology, biology, physics.

[37]  E. Rowińska-Zakrzewska,et al.  The prognostic significance of bone marrow metastases in small cell lung cancer patients. , 1993, Lung cancer.

[38]  Joe Y. Chang,et al.  Phase 1 study of dose escalation in hypofractionated proton beam therapy for non-small cell lung cancer. , 2013, International journal of radiation oncology, biology, physics.

[39]  O. Brodin,et al.  Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials , 1995 .